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Background and objectives: Cancer patients undergo routine imaging studies much more than 
others. The widespread use of the recently introduced multi-detector CT scanners has resulted 
in an increasing number of incidentally diagnosed pulmonary embolism (PE) in asymptomatic 
cancer patients. The significance and clinical outcome of such incidental PE is described.
Methods: Both radiology department and hospital databases were searched for all cancer 
patients with a diagnosis of incidental PE. CT scans were performed using a 64-slice scanner 
with a 5.0 mm slice thickness.
Results: During the study period, 34 patients with incidental PE were identified. The mean 
age (±SD) was 57.7 (±12.4) years. All patients had active cancer, gastric, lung, colorectal, and 
lymphomas being the most frequent. Most patients had advanced-stage disease at the time of 
PE diagnosis; 26 (77%) patients had stage IV , whereas only 3 patients had stages I or II disease. 
Twenty-seven (79%) patients had their PE while undergoing active treatment with chemotherapy 
(68%) or radiotherapy (12%); none, however, were on hormonal therapy. Most (74%) patients 
had their PE diagnosed without history of recent hospital admission. Except for 5 (15%), all 
other patients were anticoagulated. With follow-up, 2 patients developed   recurrent PE, 2   others 
had clinical and echocardiographic evidence of pulmonary hypertension, and 9 (26%) died 
  suddenly within 30 days of the diagnosis of incidental PE; 2 of these where among the 5 patients 
who were not anticoagulated.
Conclusion: Incidental PE in cancer patients is increasingly encountered. Similar to 
  symptomatic PE, many were diagnosed in patients with advanced stage disease and while 
undergoing active anti-cancer therapy. A significant percentage of patients had recurrent emboli, 
pulmonary hypertension, and sudden death.
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Introduction
Deep vein thrombosis (DVT) and pulmonary embolism (PE), collectively known as 
venous thromboembolism (VTE), are relatively common. Given its silent nature, the 
incidence, prevalence, and mortality rates of VTE are probably underestimated.1
Cancer and its treatment are recognized risk factors for VTE. Some studies have 
reported a 6-fold increased risk of VTE in patients with cancer compared with those 
without.2 Active cancer accounts for almost 20% of all new VTE events occurring in 
the community.3 The risk of VTE varies by cancer type and is especially high among 
patients with malignant brain tumors, and adenocarcinoma of the ovary, pancreas, 
colon, stomach, lung, and prostate.4Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
154
Abdel-Razeq et al
Cancer patients undergo routine imaging studies much 
more than others; these imaging studies, which usually 
include CT scans of the chest, are done to assess the extent 
of the disease (staging), assess the response to cancer therapy, 
or to screen for metastasis. The widespread use of the 
recently introduced multi-detector CT scanners has resulted 
in improved resolution and much better visualization even of 
peripheral pulmonary vessels. Venous thromboembolisms, 
including PE, in asymptomatic patients are well-recognized 
clinical entities, and it is believed that most fatal PE are not 
suspected clinically and are not treated.5,6
Many recent reports have addressed the issue of 
incidentally diagnosed PE; however, few were in cancer 
patients. The significance and clinical outcome of 
asymptomatic PE diagnosed incidentally in such high-risk 
patients are not fully characterized. Treatment decisions 
are not clear, either. In this report, we will describe the 
characteristics of 34 incidentally diagnosed PE in patients 
undergoing staging and related work-up for cancer.
Materials and methods
A hospital database (King Hussein Cancer Center, Amman, 
Jordan) was searched for all patients with a diagnosis of 
incidental PE, which was defined as radiologically detected 
PE on imaging studies done for reasons other than confirming 
or excluding such diagnosis. The radiology database was 
also queried for all CT reports with similar diagnosis. 
To further identify our study patients, medical records and 
radiology reports of all patients were reviewed by at least 
2 authors to determine the indication for the CT, tumor type, 
stage, and anti-cancer therapy particularly in relation to PE 
development, including surgery, chemotherapy, and radiation 
therapy. Clinical notes were also reviewed for possible risk 
factors or clues that would have suggested a diagnosis of 
PE. Active treatment, when offered, for incidental PE was 
recorded and final outcomes were identified.
CT was performed using a Philips Briliance-64 slice 
scanner with a 5.0 mm slice thickness. The contrast volume 
was 10 mL infused at a rate of 3.0 mL per second.
Descriptive statistical analysis was performed to present 
patients’ demographic and clinical characteristics, treatment 
rate, and clinical outcome.
Results
From January 2005 through June 2010, 34 patients, 14 
(41%) males and 20 (59%) females, with incidental PE 
were identified. The mean age (±SD) of the whole group 
was 57.7 (±12.4) years. All patients had a pathologically 
confirmed diagnosis of cancer; the most frequent cancers 
were gastric, diagnosed in 6 (18%) patients, followed by 
lung cancer in 5 (15%), and colorectal and lymphoma in 
4 (12%) patients each. The indications for CT scan were: 
initial staging in 8 (24%), response evaluation in 22 (64%), 
and surveillance for metastasis in 4 (12%). The   majority 
of patients had advanced-stage disease at time of PE 
  diagnosis; 26 (77%) patients had stage IV and 5 (15%) had 
stage III disease, whereas only 3 patients had stages I or II 
disease. Twenty-seven (79%) patients had their PE while 
undergoing active treatment with chemotherapy (68%) or 
radiotherapy (12%); none, however, were on hormonal 
therapy (Table 1).
Only 2 patients had a prior diagnosis of DVT and both 
where on oral anticoagulants. Twenty-five (74%) patients had 
their incidental PE diagnosed while ambulatory and without 
history of recent hospital admission. Following the incidental 
diagnosis of PE, retrospective evaluation of the patients’ 
medical records showed clinical evidence of DVT in 6 (18%) 
patients while 18 (53%) had some respiratory symptoms 
(shortness of breath, chest pain, or hemoptysis alone or in 
Table 1 Patients’ characteristics 
gender
  Male 14 (41.2%)
  Female 20 (58.8%)
  Total 34 (100%)
Age (years)
  Range 27–82
  Mean (±sD) 57.7 (±12.4)
  Median 59
Primary cancer
  gastric 6 (17.6%)
  Lung 5 (14.7%)
  colorectal 4 (11.8%)
  Lymphoma 4 (11.8%)
  Breast 3 (8.8%)
  Ovarian 3 (8.8%)
  Melanoma 2 (5.9%)
  Others 7 (20.6%)
indication for cT
  initial staging 4 (11.8%)
  Response evaluation 22 (64.7%)
  surveillance of metastasis 8 (23.5%)
stage
 i 1 (2.9%)
  ii 2 (5.9%)
  iii 5 (14.7%)
  iV 26 (76.5%)
Oncologic treatment
  chemotherapy 23 (67.6%)
  Radiotherapy 4 (11.8%)
  Hormonal therapy 0 (0.0%)
  none 7 (20.6%)Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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combination) at time of incidental PE diagnosis. Tachycardia, 
electrocardiogram (EKG) changes, and   hypoxemia were 
detected in 16 (47%), 10 (29%), and 9 (26%), respectively. 
Pulmonary embolism was central in 18 (53%) while it was 
detected in a peripheral pulmonary artery in the remaining 
16 (47%) patients (Table 2).
Following the diagnosis of PE, 29 (85%) patients were 
anticoagulated with a low-molecular-weight heparin with 
or without oral anticoagulant. The 5 patients who were 
not anticoagulated were also reviewed; all had stage IV 
disease and 4 were undergoing active cancer treatment 
with   chemotherapy or radiotherapy. Except for 5 (18%), all 
patients were treated on an outpatient setting without a need 
for hospitalization.
The clinical courses of the patients were followed; 
2 patients developed recurrent PE documented on   imaging 
studies following clinical presentation suggestive of PE, 
while 2 others had clinical and echocardiographic   evidence 
of pulmonary hypertension. Surprisingly, 9 (26%) died 
suddenly within 30 days of the diagnosis, 2 of whom 
where among the 5 patients who were not anticoagulated 
(Table 3).
Discussion
Incidental PE is not an uncommon diagnosis in clinical 
practice, especially in high-risk patients like those with 
cancer. Depending on the patient population studied, the 
diagnostic criteria, and technique used, the incidence of 
incidental PE varies, some studies describing an incidence 
as high as 4.3%.7,8
In a recent study, the medical records of 1921 consecutive 
cancer patients starting chemotherapy were reviewed; 
overall, there were 101 (5.3%) VTE, 62 (3.2%) of which were 
incidental; more than one-third (24/62) were PE.9 In another 
retrospective study that included 435 consecutive staging CT 
chest, abdomen, and pelvis scans performed on a variety of 
cancer patients, PE was detected in 13 (3.3%) while 6.8% 
had unsuspected iliofemoral and 1.2% had unsuspected 
common iliac DVT; both DVT and PE were more common 
in hospitalized patients (P = 0.002, 0.004; relative risk 
[RR] = 1.6, 2.1, respectively) and in those with advanced 
disease (P = 0.001, 0.01; RR = 2.2, 1.8, respectively).10 
The variation in incidence rate of unsuspected PE can be 
attributed to the heterogeneity of the patient population 
studied. However, the technique of the CT scan, including 
slice thickness, plays a significant role, too. A recently 
published meta-analysis of 12 studies addressing incidental, 
asymptomatic PE that included more than 10,000 patients 
found a prevalence of 2.0% (95% CI 1.0, 3.4) when using 
CT scans with $5 mm slice thickness compared with a 
prevalence of 3.0% (95% CI 2.0, 4.0) when using scans 
with ,5 mm slice thickness.11 This issue was also addressed 
in another study, in which incidental PE was more frequent 
with a 1 mm slice thickness scans (6%) comparison with 
the 2 to 3 mm slice thickness scans (4.7%), although this 
difference was not statistically significant.12
Silent PE following a diagnosis of DVT is not the same 
as incidental PE under discussion in this report. Patients 
with DVT, especially high-risk ones, might develop a silent 
PE that can be detected by imaging studies in a relatively 
high percentage of such patients. In a systemic review of 
published literature, silent PE was diagnosed in 1665 (32%) 
of 5233 patients with DVT. The incidence of silent PE was 
higher with proximal DVT than with distal DVT.13
Previous work in cancer patients with symptomatic VTE 
highlighted certain clinical variables that can identify cancer 
patients at higher risk of developing VTE. First, the risk of 
VTE is highest among certain cancer types like brain, ovar-
ian, gastric, and pancreatic tumors,14,15 but lower in sites 
such as skin, breast, and thyroid.16,17 Second, the risk of 
Table 2 clinical characteristics 
Respiratory symptomsa
  shortness of breath 16 (40.0%)
  chest pain 6 (15.0%)
  Hemoptysis 2 (5.0%)
  none 16 (40.0%)
immobilization 10 (29.4%)
clinical evidence of DVT 6 (17.6%)
Hypoxemia 9 (26.5%)
eKg changes 10 (29.4%)
Radiologic features
  central Pe 18 (52.9%)
  Peripheral Pe 16 (47.1%)
Note:  aBecause  some  patients  had  more  than  one  respiratory  symptom,  total 
number is more than 34.
Abbreviations: DVT, deep vein thrombosis; eKg, electrocardiogram; Pe, pul  mo-
nary embolism.
Table 3 Treatment and outcome 
Treatment for Pe
  Anticoagulation  29 (85.3%)
  no anticoagulation 5 (14.7%)
Outcome
  Recurrent Pe 2 (5.9%)
  Pulmonary hypertension 2 (5.9%)
  sudden death 9 (26.5%)
Treatment given
  inpatient 15 (44.1%)
  Outpatient 19 (55.9%)
Abbreviation: Pe, pulmonary embolism.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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VTE is highest during the first 3 to 6 months after the initial 
  diagnosis of cancer.18 Third, the risk varies with the stage of 
the disease, being much higher with advanced stage than with 
early stage disease.18 Fourth, the risk is also higher among 
cancer patients on active treatment with chemotherapy or 
radiotherapy.19
Similar to what has been reported in symptomatic VTE 
in cancer patients discussed above, most of our incidental 
PE were diagnosed in patients undergoing active cancer 
treatment with chemotherapy and radiation therapy and 
during the early phases of their cancer, as shown by the fact 
that almost 25% had such diagnosis while undergoing initial 
staging work-up and 64% had their incidental PE diagnosed 
while undergoing imaging studies to evaluate response to 
active treatment. Additionally, we may conclude that other 
important tumor characteristics such as disease stage are 
also important factors in incidental PE. The presence of 
advanced stage disease, identified in more than 75% of our 
patients, is associated with higher risk of PE. However, 
given the relatively small number of reported cases of inci-
dental PE and the selection bias related to higher frequency 
of imaging studies done for certain tumor types, by virtue 
of the disease itself or the treatment given for lymphomas 
and lung cancer for example, it would be difficult to state 
that incidental PE is more common in certain tumor types 
or to suggest or recommend routine evaluation or even 
closer follow-up.
The management of incidental PE might not be clear 
in the mind of practicing physicians. Current clinical 
guidelines published by the American College of Chest 
Physicians   recommend the same initial and same   long-term 
anticoagulant therapy for patients who are   unexpectedly found 
to have asymptomatic PE as for patients with   symptomatic 
PE.20 However, others argued that a similar outcome can be 
achieved without anticoagulation.21 In one study, Engelke 
et al retrospectively assessed the outcome of PE treatment 
in a group of 96 patients, many of whom had unexpected PE 
and many were cancer patients.   Forty-nine (51%) patients 
received therapeutic anticoagulation while 26 (27%) received 
no treatment; 21 (22%) patients,   however, were given only 
a prophylactic dose of anticoagulation. PE severity was 
higher in patients with therapeutic anticoagulation than in 
those without (P , 0.001). Bleeding complications were 
more frequent with therapeutic anticoagulation (2 early 
deaths, 5 major nonfatal hemorrhages) than without (1 minor 
hemorrhage; P = 0.037). There were 8 early deaths, 7 in 
the therapeutic anticoagulation group and 1 in the group 
without anticoagulation (P = 0.037). The authors concluded 
that clinically unsuspected PE may remain undetected at 
routine chest CT and such patients have favorable short-term 
outcome without therapeutic anticoagulation.21 However, 
physicians should be careful when applying such findings 
in clinical practice.
Though defined as incidental, our study showed that 
with close questioning or review of their medical records, 
some of our study patients had symptoms or signs that could 
have been attributed to PE. Among our cases, respiratory 
symptoms in form of shortness of breath, chest pain, and 
hemoptysis were identified in 40%, and 25% or more of the 
patients had hypoxemia or EKG changes.
Our study also adds to the growing evidence that 
ambulatory cancer patients can be at risk for VTE. In our 
study, 76% of the patients had their PE without history 
of recent hospitalization. Non-hospitalized, ambulatory 
cancer patients on active anti-cancer therapy can be at 
high risk for VTE, too; current guidelines, however, do not 
recommend anticoagulant prophylaxis for such patients. 
Khorana et al tried to establish a risk assessment model for 
VTE prophylaxis in ambulatory cancer patients after the 
initiation of chemotherapy. The site of the primary tumor, 
platelet count, leukocyte counts, hemoglobin level, use of 
erythropoiesis stimulating agents, and body mass index were 
found to be predictive factors for the occurrence of VTE.22 
In another recent study by the Vienna Cancer and Thrombosis 
Study Group, investigators reported that elevated serum 
P-selectin levels predicted VTE in 687 newly diagnosed 
ambulatory cancer patients. The cumulative probability of 
VTE after 6 months of follow-up was 11.9% in patients with 
high serum P-selectin compared with 3.7% in those with low 
levels (P = 0.002).23
Our patient population in this study, and others similar 
previously, are too small to draw firm conclusions about 
these associated risk factors. More work is needed to further 
address the issue of VTE in ambulatory cancer patients.
The retrospective nature of our study and the active 
anticoagulation of the majority (85%) of our study patients 
did not allow us to trace the clinical relevance of incidental 
PE. Previous studies have shown that patients with cancer 
have more than a 4-fold higher risk of dying after a acute 
thrombotic event than cancer patients without.24,25 In one 
study, Sørensen et al found that 1-year survival rate for 
  cancer patients with thrombosis was 12% compared with 
36% in cancer patients without VTE (P , 0.001).26 Though 
our study cannot confirm a similar negative impact of inci-
dental PE, our findings offer some clues to suggest a similar 
poor outcome; 25% of our patients had sudden death while Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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another 12% had recurrent PE or pulmonary hypertension. 
Few other studies have attempted to provide clues on the 
natural history of incidental PE; however, many were in 
non-cancer patients. In one study, and at clinical follow-up 
that varied from 2 days to 24 months, symptomatic VTE 
events occurred in 4 of 12 patients in whom incidental 
PE were not identified at the time of CT scan.27 In another 
study, Storto et al found that progression of PE occurred at 
follow-up CT scan in 1 of 4 patients in whom PE was not 
identified at the time of the original imaging study. None 
of these patients were anticoagulated for their incidental 
PE.28 In a more recent study, O’Connell et al found that 
cancer patients with   incidental PE had an increased risk of 
death (hazard ratio 1.79; 95% CI 1.10, 2.90) and that such 
incidental PE appeared to confer a poorer survival (5 vs 
14 months; P = 0.0009).29
Our study is not without limitations. Alhough it is 
among the largest studies to include cancer patients with 
incidental PE, the small number of patients studied and its 
retrospective nature may not allow reliable conclusions. 
Currently, our group is prospectively collecting data on 
unsuspected PE diagnosed in CT studies done for reasons 
other than   diagnosing PE. The prospective nature of this 
ongoing study will allow us to draw conclusions on clinical 
and other associated risk factors, including some of those 
addressed in symptomatic PE.
In conclusion, incidental PE in cancer patients is 
  increasingly encountered. Similar to symptomatic PE, 
many were diagnosed in patients with advanced stage 
disease and while undergoing active treatment with chemo-
therapy.   Clinical outcomes, in the form of recurrent emboli, 
  pulmonary hypertension, and sudden death, appear to be 
similar to symptomatic PE.
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